Discussion
The following data were obtained in omental adipose tissue in this study: (i) H3K9 acetylation at the promoter regions of Dbp was significantly reduced in the DM2 group compared with in the non-DM group; (ii) the mRNA expressions of DBP and novel PPAR-γ were significantly lower in the DM2 group than in the non-DM group and (iii) positive correlation was detected between DBP mRNA and novel PPAR-γ mRNA expressions.
It is well known that histone modifications, such as acetylation, exert a major role of transcriptional activity of downstream genes,17 and that a high intensity of H3K9 acetylation is detected around the transcription start site of downstream genes.18 19 Our previous studies showed that acetylation level of histone H3K9 at the promoter region of Dbp and DBP mRNA expression in epididymal adipose tissue were significantly reduced in ob/ob mice, one of the animal models of human DM2.9 10 We also found that histone deacetylases (HDACs) inhibitors increased DBP mRNA expression and decreased blood glucose in these animals with diabetes. In healthy cells, there is a tightly controlled equilibrium between the effects of histone acetyltransferases (HATs) and HDACs enabling histone (de)acetylation and the dynamic control of gene transcription.20 21 In this study, we demonstrated for the first time that H3K9 acetylation at the promoter regions of Dbp in omental adipose tissue was significantly reduced in patients with DM2. However, a mechanism of the reduction of H3K9 acetylation is not clear and remains to be determined. An imbalance between the activities of HATs and HDACs in favor of histone deacetylation is considered to be pathogenic in disease progression,20 21 which leads us to speculate that an imbalance between the activities of HATs and HDACs in the promoter regions of Dbp is also involved in the etiology of DM2. To address the issue, further clinical studies using drugs such as HDACs inhibitor are warranted in patients with DM2.
Tissue distribution and functions of PPAR-γ isoforms in mice are as follows: PPAR-γ1 is ubiquitously expressed except for adipose tissue and is involved in organ development such as placenta and heart. PPAR-γ1sv, a homolog corresponding to human novel PPAR-γ, and PPAR-γ2 are adipocyte-specific and synergistically regulate the early stage of adipocyte differentiation.12 22 In this study, only novel PPAR-γ has altered expression in omental adipose tissue in patients with DM2 with gastric cancer. However, there were no data which might explain the finding.
In this study, mRNA expressions of DBP and novel PPAR-γ were significantly lower in the DM2 group, which are similar with previous findings obtained in ob/ob mice.10 DBP is reported to bind directly to D-sites of promoter region of Ppar-γ and enhance the mRNA expression of the gene.23 Because the significant positive correlation was detected between DBP mRNA and novel PPAR-γ mRNA expressions, the reduction in novel PPAR-γ mRNA expression might depend on a decreased DBP protein.
Our previous study showed that HDACs inhibition increased the mRNA expressions of DBP and subsequent PPAR-γ1sv, the homolog of human novel PPAR-γ, in epididymal adipose tissue in ob/ob mice, but not in the control animals (C57BL/6JHamSlc).10 The following findings were also obtained by HDACs inhibition in ob/ob mice: (i) increased proportion of smaller size of preadipocytes in epididymal adipose tissue, which might be mediated through the action of elevated PPAR-γ1sv protein12; (ii) elevated plasma adiponectin concentration, which is mainly secreted by small size adipose tissue24; (iii) improvement of peripheral insulin signal transduction measured by phosphorylation of insulin-receptor substrate 1 (IRS-1) and AKT in muscle by the elevated plasma adiponectin concentration.25 In this study, patients with DM2 were treated with antidiabetic drugs including sulfonylureas and DPP-4 inhibitors until 1 day before surgery. Because these antidiabetic drugs are reported to elevate plasma adiponectin concentration,26–28 metabolic variables such as adiponectin, leptin, blood glucose and HbA1c were not measured in the present study. Therefore, an influence of reduced H3K9 acetylation at the promoter regions of Dbp in visceral adipose tissue on glucose metabolism could not be evaluated. Further studies including patients with DM2 without any antidiabetic drugs are needed to evaluate a potential influence of a reduced DBP protein on glucose metabolism.
Subcutaneous adipose tissue represents the normal physiological buffer for excess energy intake with limited energy expenditure. It acts as a metabolic sink where excess free fatty acids and glycerol are stored as triglycerides.29 Previous study reported that clock genes expressions are decreased in subcutaneous adipose tissue in patients with obesity having DM2,30 but other study showed that clock genes expressions are maintained in these patients.31 Omental and mesenteric adipose tissue are two major components of visceral fat. Their profiles are summarized as13: (i) omentum is the fatty apron attached to the greater curvature of the stomach, and mesentery is the fat containing the arteries and veins supplying the small and large intestine and (ii) visceral tissue adipocytes are more metabolically active, more sensitive to lipolysis and more insulin resistance than subcutaneous adipocytes. Previous study in patients without DM2 showed that the mRNA expressions of CLOCK, BMAL1, PER1, PER2 and CRY1 in omental adipose tissue were similar between obese and lean.32 The present study added data indicating that DM2 might not alter the expressions of these clock genes in omental and mesenteric adipose tissue.
To our knowledge, data concerning a potential different role of omental and mesenteric adipose tissue in insulin resistance of DM2 are largely lacking due to the difficulty in obtaining these tissue.33 34 In addition, these two studies provided diverse findings about the role of mesenteric33 and omentum34 adipose tissue in insulin resistance. In this study, the mRNA expressions of DBP and subsequent novel PPAR-γ in the patients with DM2 were significantly lower in the omental adipose tissue than in the mesenteric adipose tissue. On the other hand, Yang et al reported that PPAR-γ mRNA expression was upregulated in the mesenteric adipose tissue in patients with obesity having DM2.14 However, obesity per se is reported to elevate the PPAR-γ mRNA expression in visceral adipose tissue,32 which might partially explain the elevated expression of PPAR-γ mRNA in the omental adipose tissue in the study by Yang et al (mean BMI 44.9 kg/m2). Patients with obesity were not included in this study (mean BMI 24.0 kg/m2). Therefore, a big difference in BMI between our study patients and patients in the study by Yang et al might cause diverse influence on PPAR-γ mRNA expression in the omental adipose tissue.
Limitations
Gender differences are reported in chrono-physiological35 and chrono-pharmacological36 profiles in human subjects. In this study, the ratio of male/female in the DM2-gastric cancer group is larger (but not significantly) than that in the non-DM-gastric cancer group. Therefore, gender differences cannot be excluded as the cause of the significant difference between the DM2 and non-DM groups for the omental fat.
There were no significant seasonal differences in the number of patients enrolled in this study between the non-DM and DM2 groups. However, season would change the length of day light that a patient might be exposed and this would influence circadian gene expression profiles.
It is well-known that impaired adiponectin secretion is involved in the pathogenesis of insulin resistance, which leads to hyperinsulinemia. Serum insulin did not elevate in the patients with DM2 in this study. Therefore, a study involving patients with hyperinsulinemia is warranted for further evaluation of Dbp expression in visceral adipose tissue in patients with DM2.
Eating patterns may be strongly altered in patients with gastric cancer, which were not controlled before surgery in this study. Because a high-fat diet is reported to cause a phase advance in the mRNA expression of DBP,37 a difference in eating pattern in each patient with gastric cancer might affect Dbp gene expression in omental adipose tissue. Further study involving patients with gastric cancer under a control of eating pattern is needed.
Patients with cancer may lose body weight which may affect adipose tissue gene expression, and they may also undergo various diagnostic procedures. Therefore, whether the present findings also apply to patients with DM2 without cancer remains to be determined.
Clock genes mRNA expression showed a profound diurnal rhythm in subcutaneous adipose tissue in patients with DM2.30 To avoid the potential diurnal rhythm of clock genes in visceral adipose tissue, samples were obtained within relatively narrow o’clock time range (10:40–13:40) in this study. However, it remains to be determined whether the differences in DBP mRNA expression between DM2 group and the control group also persist throughout the circadian cycle.
In summary, the present study showed that H3K9 acetylation at the promoter regions of Dbp in omental adipose tissue was significantly reduced in patients with DM2. Consequently, mRNA expressions of DBP and novel PPAR-γ were significantly lower in patients with DM2. These changes were not detected in mesenteric adipose tissue. Because adiponectin secretion is reported to be enhanced through the PPAR-γ-related mechanism, this study supports the hypothesis that omental adipose tissue is involved in the mechanism of DM2.